Covid 19 Protein-Based Vaccine Candidate Shows Mind-Blowing Efficiency Against Delta Variant In Trial

Covid 19 Protein-Based Vaccine Candidate Shows Mind-Blowing Efficiency Against Delta Variant In Trial
SHARE

There’s more hopeful data about the coronavirus vaccines that could make many people excited these days. Just earlier today, we revealed that some pretty great news might make a lot of people’s day.

USA Today just noted that Johnson & Johnson released new data, and this shows the fact that a booster dose of its vaccine given two months after the one-shot vaccine provides 94% protection against moderate-to-severe covid symptoms.

J&J cited three studies of the vaccine and said:

“the booster shot offers 100% protection against severe or critical symptoms.”

Anyway, now, new info has been released that brings even more hope that the nightmare could be ending soon thanks to the efficient vaccines. 

New protein-based vaccine shows promising efficiency 

Check out a really relevant tweet that has been made in this direction.

 

Official data released by her farmaceutical company and cited by the important publication Business Insider shows that Clover Biopharmaceuticals, Ltd. which is a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, and CEPI, the Coalition for Epidemic Preparedness Innovations, has just revealed that Clover’s adjuvanted protein-based covid 19 vaccine candidate, SCB-2019 “achieved the primary efficacy endpoint and secondary efficacy endpoints in SPECTRA, a global pivotal Phase 2/3 clinical trial.”

The vaccine shows efficiency against the Delta variant 

Check out what the online publication mentioned above noted: 

“Vaccine efficacy was successfully demonstrated in an environment where 100% of SARS-CoV-2 strains observed in the efficacy analysis were variants.”

Business Insider concluded their piece by noting that the overall efficiency was 67% against the covid 19 of any severity caused by any strain that was included in the studies.

Source: Pixabay
Source: Pixabay

The vaccine candidate is one of the first ones that show important efficiency against the Delta variant. 


SHARE
Rada Mateescu

Passionate about subjects from the science and health-related areas, Rada has been blogging for about ten years and at Health Thoroughfare, she's covering the latest news on these niches.

Share this post

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.